Recent advances in esophageal cancer gene therapy

Annals of Thoracic and Cardiovascular Surgery

Volumn 14, Issue 1, 2008, Pages 3-8

  Shimada, Hideaki ^a   Matsushita, Kazuyuki ^a   Tagawa, Masatoshi ^b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Angiogenesis; Clinical study; Esophageal cancer; Gene therapy; P53

Indexed keywords

VIRUS VACCINE;

ANIMAL; CLINICAL TRIAL; ESOPHAGUS TUMOR; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VIRAL VACCINES;

EID: 43249116915     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, et al. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg 2006; 30: 1441- 9.
2. Shinoda M, Hatooka S, Mori S, Mitsudomi T. Clinical aspects of multimodality therapy for respectable locoregional esophageal cancer. Ann Thorac Cardiovasc Surg 2006; 12: 234-41.
3. Nabeya Y, Ochiai T, Matsubara H, Okazumi S, Shiratori T, et al. Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Dis Esophagus 2005; 18: 388-97.
4. Shimada H, Shiratori T, Okazumi S, Matsubara H, Nabeya Y, et al. Has surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience-. J Am Coll Surg 2008; 206: 48-56.
5. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990; 87: 9958-61.
6. Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, et al. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among highrisk populations in Henan, China. Cancer Res 1994; 54: 4342-6.
7. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83: 7-18.
8. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002; 132: 41-7. (Pubitemid 34787820)
9. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133: 24-31.
10. Shimada H, Okazumi S, Takeda A, Nabeya Y, Matsubara H, et al. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today 2001; 31: 591-6.
11. Vallböhmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19: 425-32.
12. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
13. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-6.
14. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-9.
15. Shimada H, Takeda A, Shiratori T, Nabeya Y, Okazumi S, et al. Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma. Cancer 2002; 94: 1947-54. (Pubitemid 34270047)
16. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002; 86: 552-7.
17. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, et al. Therapeutic effect of a retroviral wildtype p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-62.
18. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5: 1079-88.
19. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996; 2: 1665-71.
20. Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, et al. A phase I study of adenovirusmediated wild- type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9: 2075-82.
21. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-71.
22. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609-22
23. Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, et al. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther 2006; 13: 169-81.
24. Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 2006; 24: 2052-8.
25. Shimada H, Shimizu T, Ochiai T, Liu TL, Sashiyama H, et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001; 31: 597-604.
26. Shimada H, Matsubara H, Ochiai T, Shiratori T, Miyazaki S, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006; 97: 554-61.
27. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93-101.
28. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750-8.
29. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12 (3 Pt 1): 878-87.
30. Matsumoto K, Nakamura T. Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 2005; 333: 316-27.
31. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem Biophys Res Commun 2007; 358: 117-23.
32. Ogura Y, Mizumoto K, Nagai E, Murakami M, Inadome N, et al. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther 2006; 13: 520-9.
33. Shimada H, Shiratori T, Matsushita K, Ochiai T. A Phase I/II study of NK4 gene therapy for digestive squamous cell carcinoma. Proceedings of 65th Annual Meeting of the Japanese Cancer Association. 2006; pp. 267.
34. Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, et al. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther 2001; 8: 397-404.
35. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, et al. Phase I study of replication-competent adenovirus- mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-76.
36. Boucher PD, Im MM, Freytag SO, Shewach DS. A novel mechanism of synergistic cytotoxicity with 5- fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res 2006; 66: 3230-7.
37. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, et al. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3: 313-9. (Pubitemid 27112929)
38. Shimada H, Liu TL, Ochiai T, Shimizu T, Haupt Y, et al. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33 (ING1) in T. Tn human esophageal carcinoma cells. Oncogene 2002; 21: 1208-16.
39. Shimizu T, Shimada H, Ochiai T, Hamada H. Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl-transferase and herpes simplex virus thymidine kinase). Cancer Gene Ther 2001; 8: 512- 21.
40. Morley S, MacDonald G, Kirn D , Kaye S, Brown R, et al. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 2004; 10: 4357-62.
41. Tagawa M, Kawamura K, Shimozato O, Ma G, Li Q, et al. Virology- and immunology-based gene therapy for cancer. Cancer Immunol Immunother 2006; 55: 1420-5.
42. Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, et al. Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. Eur J Cancer 2004; 40: 1787-94.
43. Iwadate Y, Inoue M, Saegusa T, Tokusumi Y, Kinoh H, et al. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 2005; 11: 3821-7.
44. Yoneyama Y, Ueda Y, Akutsu Y, Matsunaga A, Shimada H, et al. Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells. Biochem Biophys Res Commun 2007; 355: 129-35.